1-4 of 4
Spencer B. Gibson, Ph.D
Close
Sort by
Journal Articles

The Role of Proteasome Inhibitors and the Trail Apoptotic Pathway in the Treatment of Chronic Lymphocytic Leukemia.

Kristin E. McCrea, BSc, Albert Kabore, Ph.D, James B. Johnston, MD, Spencer B. Gibson, Ph.D
Journal: Blood
Blood (2005) 106 (11): 5011.
https://doi.org/10.1182/blood.V106.11.5011.5011
Published: 2005
Journal Articles

The Role of Histone Acetylation and Death Receptor 5 (DR5) Expression in the Treatment of Chronic Lymphocytic Leukemia (CLL).

Bonnie A. Graham, BSc, Brenda Kuschak, M.Sc, James B. Johnston, MD, Spencer B. Gibson, Ph.D
Journal: Blood
Blood (2005) 106 (11): 5017.
https://doi.org/10.1182/blood.V106.11.5017.5017
Published: 2005
Journal Articles

Lysophosphatidic Acid (LPA) Protects Primary Chronic Lymphocytic Leukemia (CLL) Cells from Apoptosis: Role for LPA as a Survival Factor in CLL.

Spencer B. Gibson, Ph.D., Xiaojie Hu, M.S., Neil Haney, B.S., Albert F. Kabore, Ph.D., James B. Johnston, M.D.
Journal: Blood
Blood (2004) 104 (11): 4788.
https://doi.org/10.1182/blood.V104.11.4788.4788
Published: 2004
Journal Articles

Proteasome Inhibiters Up-Regulate TRAIL/Apo2L and Its Receptors Significantly Contributing to Proteasome Inhibitor-Induced Apoptosis in Primary Chronic Lymphocytic Leukemia (CLL) Cells.

Albert F. Kabore, Ph.D., Kristin McCrea, B.S., James B. Johnston, M.D., Spencer B. Gibson, Ph.D.
Journal: Blood
Blood (2004) 104 (11): 2810.
https://doi.org/10.1182/blood.V104.11.2810.2810
Published: 2004